- Home
- SI vs XFOR Comparison
SI vs XFOR Comparison
Compare SI & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SI | XFOR |
|---|---|---|
| Founded | 2009 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 377.3M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | SI | XFOR |
|---|---|---|
| Price | $17.60 | $3.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $20.80 | $9.00 |
| AVG Volume (30 Days) | 77.9K | ★ 792.4K |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,317,000.00 | $6,500,000.00 |
| Revenue This Year | $39.59 | N/A |
| Revenue Next Year | $31.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 49.63 | ★ 150.00 |
| 52 Week Low | $10.92 | $2.80 |
| 52 Week High | $24.60 | $4.83 |
Technical Indicators
Market Signals| Indicator | SI | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 37.87 |
| Support Level | $12.42 | $3.19 |
| Resistance Level | $23.08 | $3.56 |
| Average True Range (ATR) | 0.99 | 0.25 |
| MACD | -0.22 | -0.02 |
| Stochastic Oscillator | 10.30 | 31.12 |
Price Performance
Historical ComparisonAbout SI Shoulder Innovations Inc.
Shoulder Innovations Inc is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market. It currently offers advanced implant systems for shoulder arthroplasty. Its products include: InSet Total Shoulder Arthroplasty; InSet Reverse Shoulder Arthroplasty; ProVoyance Shoulder Planning Software; and InSet Tray System. Geographically, the company operates in United States and are planning to expand.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.